Digestive Diseases and Sciences

, Volume 56, Issue 1, pp 244–251 | Cite as

Sustained Renal Response to Mycophenolate Mofetil and CNI Taper Promotes Survival in Liver Transplant Patients with CNI-Related Renal Dysfunction

  • A. Kornberg
  • B. Küpper
  • K. Thrum
  • B. Krause
  • P. Büchler
  • J. Kornberg
  • A. Sappler
  • A. Altendorf-Hofmann
  • J. Wilberg
  • H. Friess
Original Article



The aim of this trial was to evaluate the impact of conversion from a calcineurin-inhibitor (CNI)-based immunosuppressive regimen to mycophenolate mofetil (MMF) and reduced-dose CNI on long-term renal function and survival in a series of 63 liver transplant patients with CNI-induced renal dysfunction.


CNI dosage was significantly tapered after introduction of 2,000 mg MMF per day. Renal function was assessed by determination of serum creatinine levels and calculated creatinine clearance (CCl). The impact of relevant clinical parameters on renal function and survival post-conversion was analyzed by univariate and multivariate analysis.


At 60 months post-conversion, mean creatinine level had significantly declined from 197.2 ± 58.3 μmol/l at baseline to 160.0 ± 76.5 μmol/l, and mean CCl has significantly increased from 38.4 ± 13.4 ml/min at baseline to 47.9 ± 21.1 ml/min (p < 0.001), respectively. Forty-six patients (73.1%) demonstrated sustained renal response to modified immunosuppression. Full-dose MMF medication (p = 0.006) and the early conversion (p = 0.02) were identified as independent predictors of persistent renal function improvement. Sustained renal response to MMF plus reduced-dose CNI was identified as the most relevant independent promoter of long-term survival (hazard ratio 6.9). Five-year survival rate post-conversion was 93.9% in renal responders and 64.3% in renal non-responders (log rank < 0.001).


Sustained renal response to MMF and CNI dose reduction promotes long-term survival in liver transplant patients with CNI-induced renal dysfunction.


Liver transplantation Mycophenolate mofetil Calcineurin inhibitor Renal function Long-term survival 


  1. 1.
    Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998;66:59–66.CrossRefPubMedGoogle Scholar
  2. 2.
    Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72:1934–1939.CrossRefPubMedGoogle Scholar
  3. 3.
    Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940.CrossRefPubMedGoogle Scholar
  4. 4.
    The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110–1115.CrossRefGoogle Scholar
  5. 5.
    Wilkinson A, Pham PT. Kidney dysfunction in the recipients of liver transplants. Liver Transpl. 2005;11(S):47–51.CrossRefGoogle Scholar
  6. 6.
    Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation. 2000;69:SS5–SS10.PubMedGoogle Scholar
  7. 7.
    Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation. 2000;69(Suppl):SS11–SS13.PubMedGoogle Scholar
  8. 8.
    Bestard O, Cruzado JM, Grinyó JM. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transpl Proc. 2005;37:3729–3732.CrossRefGoogle Scholar
  9. 9.
    Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–111.CrossRefPubMedGoogle Scholar
  10. 10.
    Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80:181–190.CrossRefGoogle Scholar
  11. 11.
    Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007;321:583–589.CrossRefPubMedGoogle Scholar
  12. 12.
    van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES. Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles? Cardiovasc Res. 2006;69:341–347.CrossRefPubMedGoogle Scholar
  13. 13.
    Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64:2047–2073.CrossRefPubMedGoogle Scholar
  14. 14.
    Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation. 2005;80(Suppl):S221–S243.CrossRefPubMedGoogle Scholar
  15. 15.
    Offermann G. Immunosuppression for long-term maintenance of renal allograft function. Drugs. 2004;64:1325–1338.CrossRefPubMedGoogle Scholar
  16. 16.
    Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl. 2005;11:750–759.CrossRefPubMedGoogle Scholar
  17. 17.
    Wiesner RH, Steffen BJ, David KM, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. Am J Transplant. 2006;6:1609–1616.CrossRefPubMedGoogle Scholar
  18. 18.
    Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet. 2001;357:609–610.CrossRefPubMedGoogle Scholar
  19. 19.
    Schlitt HJ, Barkmann A, Böker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet. 2001;357:587–591.CrossRefPubMedGoogle Scholar
  20. 20.
    Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl. 2004;10:1189–1194.CrossRefPubMedGoogle Scholar
  21. 21.
    Pageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl. 2006;12:1755–1760.CrossRefPubMedGoogle Scholar
  22. 22.
    Reich DJ, Clavien PA, Hodge EE, MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation. 2005;80:18–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Beckebaum S, Cicinnati VR, Klein CG, et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transpl Proc. 2004;36:2671–2674.CrossRefGoogle Scholar
  24. 24.
    Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation. 2003;75:186–190.CrossRefPubMedGoogle Scholar
  25. 25.
    Cantarovich M, Tzimas GN, Barkun J, Deschênes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation. 2003;76:98–102.CrossRefPubMedGoogle Scholar
  26. 26.
    Kornberg A, Küpper B, Hommann M, Scheele J. Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol. 2005;5:141–146.CrossRefPubMedGoogle Scholar
  27. 27.
    Jain A, Vekatramanan R, Eghtesad B, et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation. 2005;27(80):859–864.CrossRefGoogle Scholar
  28. 28.
    Cicinnati VR, Yu Z, Klein CG, et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients—assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther. 2007;26:1195–1208.CrossRefPubMedGoogle Scholar
  29. 29.
    Biselli M, Vitale G, Gramenzi A, et al. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transpl. 2009;23:191–198.CrossRefGoogle Scholar
  30. 30.
    Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl. 2004;10:492–502.CrossRefPubMedGoogle Scholar
  31. 31.
    DuBay D, Smith RJ, Qiu KG, Levy G, Lilly L, Therapondos G. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl. 2008;14:651–659.CrossRefPubMedGoogle Scholar
  32. 32.
    Persson H, Nordén G, Karlberg I, Friman S. Glomerular filtratio rate after liver transplantation with a low-dose cyclosporin protocol. Transpl Int. 1994;7:172–176.CrossRefPubMedGoogle Scholar
  33. 33.
    Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transpl. 2008;22:1–15.CrossRefGoogle Scholar
  34. 34.
    Baer PC, Gauer S, Hauser IA, Scherberich JE, Geiger H. Effects of mycophenolic acid on human renal proximal and distal tubular cells in vitro. Nephrol Dial Transpl. 2000;15:184–190.CrossRefGoogle Scholar
  35. 35.
    Dubus I, Vendrely B, Christophe I, et al. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int. 2002;62:857–867.CrossRefPubMedGoogle Scholar
  36. 36.
    Nankivell BJ, Wavamunno MD, Borrows RJ, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transpl. 2007;7:366–376.CrossRefGoogle Scholar
  37. 37.
    Hong MKh, Angus PW, Jones RM, Vaughan RB, Gow PJ. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transpl. 2005;19:193–198.CrossRefGoogle Scholar
  38. 38.
    Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transpl. 2001;15:402–409.CrossRefGoogle Scholar
  39. 39.
    Borrows R, Chusney G, James A, et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit. 2005;27:442–450.CrossRefPubMedGoogle Scholar
  40. 40.
    Kashyap R, Tsoulfas G, Mack C, Williamson M, Batzold P, Bozorgzadeh A. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl. 2007;13:791–796.CrossRefPubMedGoogle Scholar
  41. 41.
    Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin. 2006;22:2355–2364.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • A. Kornberg
    • 1
    • 3
  • B. Küpper
    • 2
  • K. Thrum
    • 2
  • B. Krause
    • 3
  • P. Büchler
    • 1
  • J. Kornberg
    • 3
  • A. Sappler
    • 3
  • A. Altendorf-Hofmann
    • 3
  • J. Wilberg
    • 3
  • H. Friess
    • 1
  1. 1.Department of Surgery, Klinikum Rechts der IsarTU MunichMunichGermany
  2. 2.Department of SurgeryZentralklinikum Bad BerkaBad BerkaGermany
  3. 3.Department of General, Visceral and Vascular SurgeryFSU JenaJenaGermany

Personalised recommendations